In a move that could make diabetes treatment more affordable, Canada has approved the first generic version of the widely used drug Ozempic. The medicine has been developed by Dr. Reddy’s Laboratories, marking a major milestone for the company.
The approval came from Canada’s health regulator, which confirmed that the generic drug meets all required standards for safety, quality, and effectiveness. Like the original Ozempic, it contains semaglutide, a key ingredient used to manage type 2 diabetes.
Ozempic, developed by Novo Nordisk, has become one of the most popular drugs for diabetes, and more recently, for weight management as well. However, its high cost has made it difficult for many patients to access.
This is where the generic version could make a real difference. Generic medicines are usually much cheaper than branded ones, meaning more people could afford long-term treatment. For patients who rely on regular medication, this could ease both financial stress and health risks.
Experts say this approval is significant not just for Canada, but globally. It shows that lower-cost versions of high-demand drugs can enter developed markets while maintaining quality standards. Other countries may follow a similar path if the rollout proves successful.
The move is also likely to increase competition in the fast-growing market for diabetes and weight-loss drugs. Several pharmaceutical companies are already working on similar products, and more approvals could come in the future.
Also Read: NYC Mayor urges return of Kohinoor to India
